Review anchor
Disintegrin and metalloproteinase domain-containing protein 17
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Disintegrin and metalloproteinase domain-containing protein 17
CHEMBL3706
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Disintegrin and metalloproteinase domain-containing protein 17 as ChEMBL target CHEMBL3706, mapped to UniProt P78536. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL3706
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P78536
Disintegrin and metalloproteinase domain-containing protein 17
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Disintegrin and metalloproteinase domain-containing protein 17 matters
Disintegrin and metalloproteinase domain-containing protein 17 is reviewed as Disintegrin and metalloproteinase domain-containing protein 17 (UniProt P78536); Disintegrin and metalloproteinase domain-containing protein 17 shows clinical signal disease relevance led by rheumatoid arthritis.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 1 approved drug, 3209 compounds, and 288 assays, with lead potency reaching pChEMBL 10.6.
Protein context
Disintegrin and metalloproteinase domain-containing protein 17
Disintegrin and metalloproteinase domain-containing protein 17 Sequence length is 824 aa.
Review this target as Disintegrin and metalloproteinase domain-containing protein 17, mapped to UniProt P78536. Sequence length is 824 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P78536
Protein
Disease context
rheumatoid arthritis
Disintegrin and metalloproteinase domain-containing protein 17 shows clinical signal disease relevance led by rheumatoid arthritis. 1 linked drug keep the rationale reviewable. Linked drugs include APRATASTAT.
Start review with rheumatoid arthritis because it currently carries clinical signal support. Linked drugs include APRATASTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Clinical signal
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 1 approved drug, 3209 compounds, and 288 assays for this target. The dominant activity type is IC50. CHEMBL391851 is the current potency anchor at pChEMBL 10.6.
Use CHEMBL391851 as the tractability anchor when discussing potency (pChEMBL 10.6).
Activity source · ChEMBL 36 via Core Engine
1 approved
pChEMBL 10.6
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Disintegrin and metalloproteinase domain-containing protein 17 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P78536, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why rheumatoid arthritis is currently treated as clinical signal support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
3209
Total Compounds
288
Total Assays
1
Approved Drugs
IC50: 3186.0, KI: 519.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL391851
|
10.6 | IC50 | — |
|
|
No preferred name
CHEMBL1288122
|
10.2 | Ki | — |
|
|
No preferred name
CHEMBL148169
|
10.2 | Ki | — |
|
|
No preferred name
CHEMBL1288000
|
10.2 | Ki | — |
|
|
No preferred name
CHEMBL1630098
|
10.0 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
PREDNISOLONE
CHEMBL131
|
1955 |
Source Header